Insider Selling: Solid Biosciences (NASDAQ:SLDB) Insider Sells 26,535 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Jessie Hanrahan sold 26,535 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $170,885.40. Following the completion of the transaction, the insider directly owned 82,675 shares in the company, valued at $532,427. This trade represents a 24.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jessie Hanrahan also recently made the following trade(s):

• On Monday, February 2nd, Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $170,885.40.
• On Wednesday, December 3rd, Jessie Hanrahan sold 4,483 shares of Solid Biosciences stock. The shares were sold at an average price of $5.11, for a total transaction of $22,908.13.

Solid Biosciences Price Performance

Shares of SLDB traded down $0.03 during midday trading on Monday, hitting $6.43. The stock had a trading volume of 1,032,732 shares, compared to its average volume of 984,289. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37. The stock’s 50 day moving average is $5.75 and its 200 day moving average is $5.71. The firm has a market cap of $500.96 million, a PE ratio of -2.58 and a beta of 2.67.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities research analysts expect that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP grew its position in Solid Biosciences by 97.7% in the 3rd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company’s stock valued at $18,356,000 after acquiring an additional 1,470,000 shares in the last quarter. Nantahala Capital Management LLC raised its position in Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after purchasing an additional 1,421,968 shares in the last quarter. Alyeska Investment Group L.P. increased its position in shares of Solid Biosciences by 2.6% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,682,805 shares of the company’s stock valued at $10,383,000 after purchasing an additional 41,984 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Solid Biosciences by 28.9% during the second quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company’s stock worth $7,788,000 after purchasing an additional 358,473 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Solid Biosciences by 184.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after buying an additional 979,294 shares during the last quarter. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on SLDB shares. Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Wall Street Zen lowered Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.70.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of “Moderate Buy,” which may support demand despite near-term weakness. Analyst Rating Article
• Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
• Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing

About Solid Biosciences

Solid Biosciences Inc is a clinical?stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle?stabilizing protein.

Solid’s lead investigational therapy, SGT?001, is a micro?dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno?associated virus (AAV) vector.